Brief: Bellus Health Announces Completion Of Dosing In Phase 2 Relief Trial With BLU-5937 For Treatment Of Refractory Chronic Cough
06/04/2020 22:51
April 6 (Reuters) - BELLUS Health Inc BLU.TO :
* BELLUS HEALTH ANNOUNCES COMPLETION OF DOSING IN PHASE 2
RELIEF
TRIAL WITH BLU-5937 FOR THE TREATMENT OF REFRACTORY CHRONIC
COUGH
* BELLUS HEALTH INC - TOPLINE DATA FROM PHASE 2 RELIEF TRIAL
WITH
BLU-5937 ON TRACK FOR MID-YEAR 2020
* BELLUS HEALTH INC - DECIDED TO CLOSE TRIAL EARLY DUE TO
IMPACT
OF COVID-19 PANDEMIC ON RELIEF CLINICAL TRIAL ACTIVITIES
Source text for Eikon: ID:nBwb303P5a
Further company coverage: BLU.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BELLUS Health
See all newsBrief: Bellus Health Inc. Calls Special Shareholders’ Meeting In Connection With Gsk Acquisition
Brief: Bellus Health Reports First Quarter 2023 Financial Results And Business Highlights
Press Digest: British Business - April 19
Canada Stocks: Toronto market extends winning streak on 'soft landing' hopes
Bellus soars as GSK plans to buy drug developer for $2 bln